News | October 19, 2021
Domestic growth to the fore as US weakness persists: ICICI Direct
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
The company has to approach the DCGI for approval to commence the trials
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Subscribe To Our Newsletter & Stay Updated
